Article Information
History
- December 4, 2020.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Peiying Yang1,*,
- Xiangsheng Zuo2,3,
- Shailesh Advani4,
- Bo Wei1,
- Jessica Malek2,
- R. Sue Day5 and
- Imad Shureiqi2,3,*,#
- 1Departments of Palliative, Rehabilitation, and Integrative Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas
- 2Departments of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, Texas
- 3Departments of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas
- 4Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington DC
- 5Department of Epidemiology, School of Public Health, The University of Texas Health Science Center, Houston, Texas
- ↵*Correspondence:
ishureiq{at}med.umich.edu (I.S.), Tel.: 734-647-1417, Division of Hematology and Oncology, Department of Internal Medicine, and Rogel Cancer Center, University of Michigan, Ann Arbor, MI 48109; and pyang{at}mdanderson.org (P. Yang), Tel.: 713-563-7531, Department of Palliative, Rehabilitation, and Integrative Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030.
Posted December 04, 2020.
Celecoxib Colorectal Bioavailability and Chemopreventive Response in Familial Adenomatous Polyposis Patients
